Matricelf Ltd. Logo

Matricelf Ltd.

Develops autologous, patient-specific tissue implants for regenerative medicine.

MTLF | TA

Overview

Corporate Details

ISIN(s):
IL0011767915
LEI:
Country:
Israel
Address:
3 Golda Meir Street, 7651713 Ness Zion

Description

Matricelf Ltd. is a preclinical-stage biotechnology company specializing in regenerative medicine and tissue engineering. The company develops a proprietary platform for creating fully autologous, patient-specific tissue implants. This technology combines a patient's induced Pluripotent Stem Cells (iPSCs) with a personalized, thermo-responsive hydrogel derived from their own extracellular matrix (ECM). The iPSCs are differentiated within this hydrogel to generate functional tissue. This autologous approach is designed to minimize the risk of immune rejection and provide a personalized, curative therapy. Matricelf's primary focus is on developing a one-time treatment for spinal cord injuries, aiming to bridge damaged tissue and restore lost function. The platform is also being explored for other conditions, including stroke, traumatic brain injury, and myocardial infarction.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2024-09-08 20:40
COMPANY'S PRESENTATION
Hebrew (modern) 2.3 MB
2024-09-08 20:40
COMPANY'S PRESENTATION
Russian 42.8 KB
2024-03-27 15:30
INVESTORS PRESENTATION
English 2.7 MB
2024-03-27 15:30
INVESTORS PRESENTATION
Russian 43.3 KB
2023-02-14 16:31
Corporate Presentation - February2023
English 1.1 MB
2023-02-14 16:31
Corporate Presentation - February2023
Russian 42.7 KB
2022-03-16 10:59
INVESTORS PRESENTATION
English 2.7 MB
2022-03-16 10:59
INVESTORS PRESENTATION
Russian 41.6 KB
2021-06-17 18:14
Opening of Trading On Sunday June 20, 2021, Appointment of a Market Maker
Hebrew (modern) 256.5 KB
2021-06-14 14:20
Identifying Details of New Security: MATRICELF, MATRICELF.W1
Hebrew (modern) 177.2 KB

Automate Your Workflow. Get a real-time feed of all Matricelf Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Matricelf Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Matricelf Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

SanBio Company Limited Logo
Develops regenerative cell-based therapies for neurological disorders.
Japan
4592
SANGAMO THERAPEUTICS, INC Logo
A clinical-stage genomic medicine company developing therapies for severe diseases.
United States of America
SGMO
S.Biomedics Co., Ltd. Logo
Researches and develops stem cell-based therapies for regenerative medicine.
South Korea
304360
SCANCELL HOLDINGS PLC Logo
A clinical-stage company developing novel immunotherapies for the treatment of cancer.
United Kingdom
SCLP
Scandion Oncology A/S Logo
A biotech company under liquidation that developed cancer drug resistance therapies.
Denmark
SCOL
Scanway Spolka Akcyjna Logo
Develops optical observation and machine vision systems for space and industry.
Poland
SCW
Scholar Rock Holding Corp Logo
Develops therapies for serious diseases by targeting latent protein growth factors.
United States of America
SRRK
Schrodinger, Inc. Logo
A physics-based platform accelerating molecule discovery for therapeutics and materials.
United States of America
SDGR
Develops medical hemostatic agents and AI-driven digital healthcare solutions.
South Korea
246960
Scope Fluidics S.A. Logo
Biotechnology firm that incubates and sells microfluidic diagnostic projects.
Poland
SCP

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.